Company profile: Enveric Biosciences
1.1 - Company Overview
Company description
- Provider of patient-first biotechnology solutions developing rigorously tested, novel cannabinoid medicines and mental health drug candidates, including EB-003, a neuroplastogen for severe disorders without inducing hallucinations; EB-002, a synthetic prodrug of psilocin being studied for psychiatric disorders with altered metabolic and pharmacokinetic properties; and Psybrary, an AI-optimized platform and portfolio of new chemical entities.
Products and services
- EB-002: Engineers a synthetic prodrug of psilocin for psychiatric disorders, featuring altered metabolic and pharmacokinetic properties
- EB-003: Develops a neuroplastogen drug candidate for severe mental health disorders, designed to treat without inducing hallucinations (non-hallucinogenic)
- Psybrary: Architects a platform and portfolio of new chemical entities for mental health indications, leveraging AI for optimization (AI-driven)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Enveric Biosciences
OncoVista Innovative Therapies
HQ: United States
Website
- Description: Provider of anticancer therapy development utilizing tumor-associated biomarkers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoVista Innovative Therapies company profile →
CytomX Therapeutics
HQ: United States
Website
- Description: Provider of proteolytically activated Probody therapeutics designed to activate only in cancer via tumor-specific proteases, minimizing activity in healthy tissue. Pipeline includes CX-904, a T-cell-engaging bispecific Probody targeting EGFR and CD3 in Phase 1 for advanced solid tumors; CX-2051, a conditionally activated EpCAM-targeting antibody-drug conjugate; and CX-801, an interferon alpha-2b Probody.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CytomX Therapeutics company profile →
Albireo Pharma
HQ: Sweden
Website
- Description: Provider of novel bile acid modulators and therapeutic drugs for the treatment of pediatric and adult liver diseases and gastrointestinal diseases, with a focus on rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Albireo Pharma company profile →
F-star
HQ: United Kingdom
Website
- Description: Provider of novel bispecific antibody therapeutics focused on immuno-oncology and oncology, developing bispecific antibody products to improve the standard of care, with the ability to create and develop Fcab™ antibody fragments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full F-star company profile →
MTM Laboratories
HQ: Germany
Website
- Description: Provider of ISO 9001 and 13485 certified in-vitro diagnostics for early detection and diagnosis of cervical and other cancers; headquartered in Heidelberg, Germany, with subsidiaries in the United States, France, Italy and Spain; markets proprietary CINtec Histology Kit and CINtec.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MTM Laboratories company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Enveric Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Enveric Biosciences
2.2 - Growth funds investing in similar companies to Enveric Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Enveric Biosciences
4.2 - Public trading comparable groups for Enveric Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →